Screener
Integra LifeSciences IART Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Lease liability - operating leases | 162,660 | 163,059 |
| Deferred tax liabilities | 3,470 | 5,664 |
| Other liabilities | 194,397 | 204,278 |
| Total liabilities | 2,520,113 | 2,558,538 |
| Stockholders’ equity: | ||
| Preferred stock; no par value; 15,000 authorized shares; none outstanding | — | — |
| Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively | 921 | 923 |
| Additional paid-in capital | 1,346,265 | 1,338,386 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's total liabilities?
- Integra LifeSciences (IART) reported total liabilities of $2.52B in Q2 2026.
- How has Integra LifeSciences's total liabilities changed year-over-year?
- Integra LifeSciences's total liabilities decreased by 4.2% year-over-year, from $2.63B to $2.52B.
- What is the long-term trend for Integra LifeSciences's total liabilities?
- Over 5 years (2020 to 2025), Integra LifeSciences's total liabilities has grown at a 4.0% compound annual growth rate (CAGR), from $2.1B to $2.56B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Integra LifeSciences's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude